Celcuity (NASDAQ:CELC) Earns Buy Rating from HC Wainwright

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Friday,Benzinga reports. They presently have a $27.00 target price on the stock. HC Wainwright’s target price indicates a potential upside of 110.77% from the company’s current price.

Several other equities analysts have also issued reports on CELC. Lifesci Capital initiated coverage on Celcuity in a research report on Monday, August 26th. They set an “outperform” rating and a $27.00 price target on the stock. Leerink Partners started coverage on shares of Celcuity in a report on Monday, July 22nd. They issued an “outperform” rating and a $29.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Celcuity in a report on Friday. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Finally, Stifel Nicolaus boosted their price objective on shares of Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Monday, October 7th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Celcuity currently has a consensus rating of “Buy” and a consensus target price of $29.17.

Celcuity Price Performance

CELC traded down $1.30 on Friday, reaching $12.81. The company had a trading volume of 604,977 shares, compared to its average volume of 278,299. Celcuity has a 52-week low of $11.51 and a 52-week high of $22.19. The company has a market cap of $474.35 million, a price-to-earnings ratio of -4.68 and a beta of 0.76. The company has a debt-to-equity ratio of 0.54, a quick ratio of 14.95 and a current ratio of 14.95. The business has a 50 day simple moving average of $15.23 and a 200 day simple moving average of $16.07.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.09. During the same period in the prior year, the business earned ($0.66) EPS. As a group, sell-side analysts anticipate that Celcuity will post -2.54 EPS for the current year.

Institutional Trading of Celcuity

Hedge funds and other institutional investors have recently modified their holdings of the company. nVerses Capital LLC purchased a new position in Celcuity in the 3rd quarter worth approximately $33,000. Prospera Private Wealth LLC bought a new stake in shares of Celcuity during the third quarter valued at approximately $35,000. Values First Advisors Inc. purchased a new position in shares of Celcuity in the third quarter worth $86,000. Quest Partners LLC boosted its position in shares of Celcuity by 31.3% during the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after acquiring an additional 1,379 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new position in Celcuity during the third quarter valued at $119,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.